IBL News

Prof. Dr. med. Piotr Lewczuk, Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany at Universitätsklinikum Erlangen in Germany presented his poster with regards to the relationship between mild cognitive impairment (MCI) which suggests early stage of Alzheimer's disease (MCI-AD) and Amyloid β toxic oligomer at Alzheimer's Association International Conference (AAIC 2017) held in London in July 2017.

56 CSF samples (14 patients with MCI-AD, 16 patients who suffer Alzheimer's disease (ADD) and 26 healthy controls without cognitive impairment) were collected and measured the concentration of Amyloidβ Toxic Oligomer in this research.

It has been discovered that the level of Amyloid β Toxic Oligomer in CSF with MCI-AD is higher than ADD patients who have already developing Alzheimer's disease and/or healthy controls as the result in this study.

This study suggests that measurement of level of Amyloid β Toxic Oligomer in CSF could be useful for early diagnosis of Alzheimer's disease and further research is required for the validation.

In this study, #27709 Human Amyloid β Toxic oligomer Assay Kit – IBL was used and the antibody specifically detects Amyloid β Toxic Oligomer (clones: 24b3) is used in this assay kit.

Please refer to the poster for further information.

We have an also comprehensive product lineup in Alzheimer's disease research.

It would be great if our products help your research.

Please feel free to contact us.

Immuno-Biological Laboratories Co., Ltd.
Diagnostic Research Reagent Division
Sales Support
TEL: +81-274-50-8666
Email: do-ibl@ibl-japan.co.jp